Terms: = Prostate cancer AND DDB2, Q92466, 1643, ENSG00000134574, FLJ34321 AND Treatment
19 results:
1. Patient-Reported Outcomes 12 Years after Localized prostate cancer treatment.
Donovan JL; Hamdy FC; Lane JA; Young GJ; Metcalfe C; Walsh EI; Davis M; Steuart-Feilding T; Blazeby JM; Avery KNL; Martin RM; Bollina P; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Rosario DJ; Rowe E; Mason M; Catto JWF; Peters TJ; Wade J; Turner EL; Williams NJ; Oxley J; Staffurth J; Bryant RJ; Neal DE
NEJM Evid; 2023 Apr; 2(4):EVIDoa2300018. PubMed ID: 38320051
[TBL] [Abstract] [Full Text] [Related]
2. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for prostate cancer.
Hamdy FC; Donovan JL; Lane JA; Metcalfe C; Davis M; Turner EL; Martin RM; Young GJ; Walsh EI; Bryant RJ; Bollina P; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Rosario DJ; Rowe E; Mason M; Catto JWF; Peters TJ; Oxley J; Williams NJ; Staffurth J; Neal DE;
N Engl J Med; 2023 Apr; 388(17):1547-1558. PubMed ID: 36912538
[TBL] [Abstract] [Full Text] [Related]
3. Association between obstructive sleep apnoea and cancer: a cross-sectional, population-based study of the DISCOVERY cohort.
Palm A; Theorell-Haglöw J; Isakson J; Ljunggren M; Sundh J; Ekström MP; Grote L
BMJ Open; 2023 Mar; 13(3):e064501. PubMed ID: 36868588
[TBL] [Abstract] [Full Text] [Related]
4. Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients.
Ueda T; Fujita K; Nishimoto M; Shiraishi T; Miyashita M; Kayukawa N; Nakamura Y; Sako S; Ogura R; Fujihara A; Minami T; Hongo F; Okihara K; Yoshimura K; Uemura H; Ukimura O
World J Urol; 2022 Dec; 40(12):2939-2946. PubMed ID: 36331614
[TBL] [Abstract] [Full Text] [Related]
5. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract] [Full Text] [Related]
6. Ten-year Mortality, Disease Progression, and treatment-related Side Effects in Men with Localised prostate cancer from the ProtecT Randomised Controlled Trial According to treatment Received.
Neal DE; Metcalfe C; Donovan JL; Lane JA; Davis M; Young GJ; Dutton SJ; Walsh EI; Martin RM; Peters TJ; Turner EL; Mason M; Bryant R; Bollina P; Catto J; Doherty A; Gillatt D; Gnanapragasam V; Holding P; Hughes O; Kockelbergh R; Kynaston H; Oxley J; Paul A; Paez E; Rosario DJ; Rowe E; Staffurth J; Altman DG; Hamdy FC;
Eur Urol; 2020 Mar; 77(3):320-330. PubMed ID: 31771797
[TBL] [Abstract] [Full Text] [Related]
7. MR imaging findings of the prostate gland following prostate artery embolization: results from a prospective phase 2 study.
Ali R; Gabr A; Mouli SK; Kallini JR; Riaz A; Mora R; Lewandowski RJ; Hohlastos E; Casalino DD; Hofer MD; Hamoui N; Miller FH; Hairston J; Salem R
Abdom Radiol (NY); 2019 Feb; 44(2):713-722. PubMed ID: 30196364
[TBL] [Abstract] [Full Text] [Related]
8. prostate-Specific Antigen-Based Screening for prostate cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
[TBL] [Abstract] [Full Text] [Related]
9. prostate cancer and the John West Effect.
EAU-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel
Eur Urol; 2017 Jul; 72(1):7-9. PubMed ID: 28385455
[TBL] [Abstract] [Full Text] [Related]
10. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for prostate cancer.
Donovan JL; Hamdy FC; Lane JA; Mason M; Metcalfe C; Walsh E; Blazeby JM; Peters TJ; Holding P; Bonnington S; Lennon T; Bradshaw L; Cooper D; Herbert P; Howson J; Jones A; Lyons N; Salter E; Thompson P; Tidball S; Blaikie J; Gray C; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Paul A; Powell P; Prescott S; Rosario DJ; Rowe E; Davis M; Turner EL; Martin RM; Neal DE;
N Engl J Med; 2016 Oct; 375(15):1425-1437. PubMed ID: 27626365
[TBL] [Abstract] [Full Text] [Related]
11. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized prostate cancer.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Paul A; Powell P; Prescott S; Rosario DJ; Rowe E; Neal DE;
N Engl J Med; 2016 Oct; 375(15):1415-1424. PubMed ID: 27626136
[TBL] [Abstract] [Full Text] [Related]
12. Presurgical Biomarker Performance in the Detection of Gleason Upgrading in prostate cancer.
Wittig K; Yamzon JL; Smith DD; Jeske DR; Smith SS
Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1643-1645. PubMed ID: 27543619
[TBL] [Abstract] [Full Text] [Related]
13. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
Lane A; Metcalfe C; Young GJ; Peters TJ; Blazeby J; Avery KN; Dedman D; Down L; Mason MD; Neal DE; Hamdy FC; Donovan JL;
BJU Int; 2016 Dec; 118(6):869-879. PubMed ID: 27415448
[TBL] [Abstract] [Full Text] [Related]
14. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
Lane JA; Donovan JL; Davis M; Walsh E; Dedman D; Down L; Turner EL; Mason MD; Metcalfe C; Peters TJ; Martin RM; Neal DE; Hamdy FC;
Lancet Oncol; 2014 Sep; 15(10):1109-18. PubMed ID: 25163905
[TBL] [Abstract] [Full Text] [Related]
15. ddb2 is a novel AR interacting protein and mediates AR ubiquitination/degradation.
Chang SW; Su CH; Chen HH; Huang CW; Tsao LP; Tsao YP; Chen SL
Int J Biochem Cell Biol; 2012 Nov; 44(11):1952-61. PubMed ID: 22846800
[TBL] [Abstract] [Full Text] [Related]
16. Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates.
Groome PA; Rohland SL; Siemens DR; Brundage MD; Heaton J; Mackillop WJ
Cancer; 2011 Sep; 117(17):3943-52. PubMed ID: 21858801
[TBL] [Abstract] [Full Text] [Related]
17. BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer.
De Luca P; Vazquez ES; Moiola CP; Zalazar F; Cotignola J; Gueron G; Gardner K; De Siervi A
Mol Cancer Res; 2011 Aug; 9(8):1078-90. PubMed ID: 21700680
[TBL] [Abstract] [Full Text] [Related]
18. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Chi KN; Ellard SL; Hotte SJ; Czaykowski P; Moore M; Ruether JD; Schell AJ; Taylor S; Hansen C; Gauthier I; Walsh W; Seymour L
Ann Oncol; 2008 Apr; 19(4):746-51. PubMed ID: 18056648
[TBL] [Abstract] [Full Text] [Related]
19. Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer.
Wernicke AG; Valicenti R; Dieva K; Houser C; Pequignot E
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1357-63. PubMed ID: 15590165
[TBL] [Abstract] [Full Text] [Related]
